Ellis Levine, MD Ellis Levine, MD

Ellis Levine

MD
Medical Oncology
Top Doctors 2021

Dr. Levine is a Buffalo Spree Top Doctor! See all of our physicians who made this year's list.

Top Doctors 2021

Specializing In:

Bladder Cancer Breast Cancer Prostate Cancer Testicular Cancer

Special Interests:

Novel therapies for breast and urothelial cancer

About Ellis Levine

Positions

Roswell Park Comprehensive Cancer Center

  • Professor of Oncology
  • Chief, Breast Medicine
  • Hematology/Medical Oncology Fellowship Director
  • Department of Medicine

Jacobs School of Medicine and Biomedical Sciences, University at Buffalo

  • Professor of Medicine
  • Director, Hematology/Medical Oncology Fellowship Program

Background

Education and Training:

  • MD - University of Pittsburgh, Pittsburgh, PA

Residency:

  • University of Minnesota, Minneapolis, MN

Fellowship:

  • University of Minnesota, Minneapolis, MN

Board Certification:

  • Internal Medicine, American Board of Internal Medicine
  • Medical Oncology, American Board of Internal Medicine

Honors & Awards:

  • 2005-2018 - America’s Top Doctors
  • 2018 - Susan G. Komen Hope Award for Upstate New York
Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
Learn More
Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer
Learn More
Comparing the New Anti-cancer Drug Eribulin With or Without Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
Learn More
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Learn More
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Learn More
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Learn More
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Learn More
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
Learn More
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
Learn More
Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy
Learn More
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Learn More
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Learn More
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Learn More
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Learn More
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Learn More
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Learn More
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Learn More
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Learn More
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
Learn More
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
Learn More

Clinical Trials

Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
Learn More
Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer
Learn More
Comparing the New Anti-cancer Drug Eribulin With or Without Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
Learn More
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Learn More
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Learn More
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Learn More
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Learn More
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
Learn More
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
Learn More
Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy
Learn More
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Learn More
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Learn More
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Learn More
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Learn More
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Learn More
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Learn More
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Learn More
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Learn More
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
Learn More
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
Learn More
Breast Cancer in Young Women: Family History Is the Best Indicator of Risk Can Breast Cancer Return After a Double Mastectomy? Prostate Cancer Survivor: Denny's Story Breast Cancer in Men: Owen’s Story What Happens If My Cancer Treatment Stops Working? How Research Saved My Life Detours and Delays, Then a New Route to Happiness What Happens When Pregnancy and Cancer Collide?

Featured on Cancer Talk

Breast Cancer in Young Women: Family History Is the Best Indicator of Risk
Can Breast Cancer Return After a Double Mastectomy?
Prostate Cancer Survivor: Denny's Story

Showing all3 of 8

Publications

Full Publications list on PubMed
  • Hinata N, Hussein AA, George S, Trump DL, Levine EG. Omar K, Dasgupta P, Khan MS, Hosseini A, Wiklund P, Guru KA: Impact of suboptimal neoadjuvant chemotherapy on perioperative outcomes and survival after robot-assisted radical cystectomy: A multicenter multinational study. BJU Int 119(4):605-611. 2017. [PMID: 27743481]
  • Adelson KB, Ramaswamy B, Sparano JA, Christos PJ, Wright JJ, Raptis G, Han G, Villalona M, Ma CZ, Hershman D, Baar J, Klein P, Cigler T, Budd T, Novik Y, Tan AR, Tannenbaum S, Goel A, Levine E, Shapiro CL. Andreopoulou E, Naughton M, Kalinsky K, Waxman S, Germain D: Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: A New York Cancer Consortium Trial. NPJ Breast Cancer. 2016 Dec 14;2:16037. doi: 10.1038/npjbcancer.2016.37. eCollection 2016
  • Tsai M, Lo S, Audeh W, Qamar R, Budway R, Levine E, Whitworth P, Mavromatis B, Zon R, Oldham D, Untch S. Treece T, Blumencranz L, Soliman H, PROMIS Investigators Group: PROMIS Trial: The 70-gene signature provides independent risk stratification and treatment guidance for patients classified as intermediate by the 21-gene assay. JAMA Oncol. 2018 Jan 11;4(1):e173470. doi: 10.1001/jamaoncol.2017.3470. Epub 2018 Jan 11
  • Dhakal A, Matthews CM, Levine EG, Salerno KE, Zhang F, Takabe K, Early AP, Edge SB, O'Connor T, Khoury T, Young JS, Opyrchal M. Efficacy of Palbociclib Combinations in Hormone Receptor-Positive Metastatic Breast Cancer Patients After Prior Everolimus Treatment. Clin Breast Cancer. 2018 Dec;18(6):e1401-e1405. doi: 10.1016/j.clbc.2018.04.015. Epub 2018 Apr 28.
  • Hatem Soliman, Esther Rehmus, Varsha Shah, Gordan Srkalovic, Reshma Mahtani, Ellis Levine, Blanche Mavromatis, Jayanthi Srinivasiah, Mohamad Kassar, Robert Gabordi, Rubina Qamar, Sarah Untch, Heather M. Kling, Tina Treece, William Audeh, IMPACt investigators group: MammaPrint and BluePrint Molecular Subtyping Guide Treatment Decisions in Breast Cancer: results of the IMPACt trial (submitted)